Home > Journals > Minerva Anestesiologica > Past Issues > Articles online first > Minerva Anestesiologica 2022 Mar 22

CURRENT ISSUE
 

JOURNAL TOOLS

Publishing options
eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

Original Paper   

Minerva Anestesiologica 2022 Mar 22

DOI: 10.23736/S0375-9393.22.16054-2

Copyright © 2022 EDIZIONI MINERVA MEDICA

language: English

Platelet activation state in early stages of Covid-19

Filippo CONSOLO 1, 2 , Patrizia DELLA VALLE 3, Marco SARACINO 2, Marta BONORA 1, Giovanni DONADONI 4, Fabio CICERI 1, 5, Moreno TRESOLDI 6, Armando D’ANGELO 3, Giovanni LANDONI 1, 2, Alberto ZANGRILLO 1 ,2

1 Università Vita Salute San Raffaele, Milano, Italy; 2 Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Milano, Italy; 3 Coagulation Service and Thrombosis Research Unit, IRCCS San Raffaele Scientific Institute, Milano, Italy; 4 Emergency Department, IRCCS San Raffaele Scientific Institute, Milano, Italy; 5 Hematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milano, Italy; 6 General Medicine and Advanced Care Unit, IRCCS San Raffaele Scientific Institute, Milano, Italy



BACKGROUND: Platelet activation at the early stage of COVID-19 is poorly described. The need for antiplatelet therapy in patients with COVID-19 remains controversial. We characterized the platelet activation profile in hospitalized patients at the early stage of COVID-19 using the modified prothrombinase Platelet Activation State (PAS) assay.
METHODS: Sixteen patients admitted to the emergency department of the IRCCS San Raffaele Scientific Institute (Milano, Italy) between February 8 and April 2021 were enrolled. All patients presented with respiratory symptoms and tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Platelet activation was measured via the PAS assay within 24 hours from patients’ hospital admission. Data were compared with those measured in n=24 healthy subjects (controls).
RESULTS: Platelet activation was significantly higher in COVID-19 patients with respect to controls (PAS = 0.63 [0.58-0.98]% vs. 0.46 [0.40-0.65]%, respectively; p=0.03). Of note, highest PAS values were measured in the two patients with the worst clinical outcome, i.e., death because of respiratory failure (PAS = 2.09% and 1.20%, respectively). No differences in standard coagulation parameters were noted between these two patients and those who were later discharged home.
CONCLUSIONS: This study provides evidences of significant platelet activation state at the early stage of COVID-19 and suggests that the patient-specific platelet activation profile is a reliable clinical marker to stratify COVID-19 patients at high risk of poor clinical outcome who might potentially benefit from antiplatelet therapy.


KEY WORDS: Platelet activation; COVID-19; Thromboinflammation

top of page